32O 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial
Titel:
32O 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial
Auteur:
Lorusso, D. Mouret-Reynier, M-A. Harter, P. Cropet, C. Caballero Diaz, C. Petru, E. Satoh, T. Vergote, I.B. Parma, G. Jakobi Nøttrup, T. Lebreton, C. Fasching, P.A. Pisano, C. Manso, L. Bourgeois, H. Runnebaum, I. Hardy-Bessard, A-C. Schnelzer, A. Pujade-Lauraine, E. Ray-Coquard, I.L.